Overview

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI nave.

Status:
RECRUITING

Trial end date:
2034-12-08

Target enrollment:

Participant gender:

Summary

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI nave and have not yet received chemotherapy in the mCSPC setting.

Phase:

PHASE3

Details

Lead Sponsor:

Pfizer

Treatments:

enzalutamide
PF06821497